Business
ECTRIMS 2024: Simvastatin fails to slow disability progression in SPMS - Multiple Sclerosis News Today
Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in Phase 3 trial.
By: Multiple Sclerosis News Today
- Sep 26 2024
- 0
- 0 Views
Daily treatment with high-dose simvastatin, a widely used cholesterol-lowering medication, failed to slow disability progression in adults with secondary progressive disease or SPMS, according to top… [+4973 chars]